Skip to main content
Clinical Trials/KCT0003264
KCT0003264
Recruiting
未知

Clinical research on the efficacy and safety of Gyebutang Granule combined with acupuncture on knee osteoarthritis

Semyung University0 sites100 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Semyung University
Enrollment
100
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Adults aged 40 to 69 years.
  • 2\. Those who follow the American College of Rheumatology (ACR) classification criteria for osteoarthritis of the knee and satisfy both ? and ? below.
  • ? During the last 6 months, unilateral or bilateral knee arthritic pain has been reported during weight bearing activity.
  • ? The knee arthritic pain is shown more than 40 ? on 100 ? Visual Analog Scale (VAS)
  • 3\. Those who decide to voluntarily participate in this clinical trial and agree in signing informed consent.
  • 4\. A person who is trusted and willing to cooperate with this trial for the next three months

Exclusion Criteria

  • 1\. A history of knee trauma within the last 6 months.
  • 2\. Operation history for the knee within the last 6 months.
  • 3\. Intra\-articular injections (steroids, mucus supplements, etc.) within the last 3 months.
  • 4\. The physical and diagnostic examination indicate an inflammatory arthritis such as rheumatoid arthritis, infectious disease or autoimmune disease.
  • 5\. Those who are treated with mental disorders such as depression and schizophrenia.
  • 6\. Patients with liver disease (AST or ALT \> normal range 2 times)
  • 7\. Patients with renal disease (serum creatinine \> 2\.0 ? / ?)
  • 8\. Those who have other diseases that may interfere with treatment, such as serious gastrointestinal diseases, cardiovascular diseases, hypertension, diabetes, kidney disease, liver disease, thyroid dysfunction etc.
  • 9\. Those who take restrictive disease, contraindication, hypersensitivity in using the prescription of non\-steroidal anti\-inflammatory drugs (NSAIDs).
  • 10\. Pregnant and lactating women.

Outcomes

Primary Outcomes

Not specified

Similar Trials